GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

ABL Bio 298380.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

35,600

-1.25%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩79.35bn

FY2016FY2025

Net income

−₩37.81bn

FY2016FY2025

Free cash flow

−₩61.92bn

FY2016FY2025

Shareholders' equity

₩154.72bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩79.35bn₩33.40bn₩65.55bn₩67.30bn₩5.33bn₩8.10bn₩3.99bn₩1.26bn₩71.4m—
Gross profit₩79.35bn₩33.40bn₩65.55bn₩67.30bn₩5.33bn₩8.10bn₩3.96bn₩1.15bn₩4.1m—
Research and development₩93.01bn₩74.08bn₩52.03bn₩48.42bn₩41.03bn₩52.79bn₩39.62bn₩18.09bn₩6.67bn—
Operating income−₩40.28bn−₩59.38bn−₩2.62bn₩906.5m−₩52.31bn−₩59.65bn−₩40.43bn−₩24.03bn−₩9.65bn−₩3.52bn
Net income−₩37.81bn−₩55.53bn−₩2.65bn₩3.21bn−₩43.56bn−₩55.61bn−₩37.00bn−₩117.23bn−₩74.73bn−₩13.68bn
Diluted earnings per share-685.83-1,150.11-55.2667.33-924.34-1,202.39-816.82-2,629.33-3,874.39-709.45

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩280.93bn₩231.98bn₩160.14bn₩185.18bn₩65.45bn₩99.89bn₩142.90bn₩168.87bn₩20.37bn₩7.53bn
Cash and short-term investments—₩140.66bn₩71.15bn₩78.31bn₩43.65bn₩70.39bn₩133.29bn₩154.90bn₩9.17bn₩5.34bn
Total liabilities₩124.24bn₩64.70bn₩86.07bn₩115.67bn₩9.50bn₩9.23bn₩10.89bn₩11.91bn₩106.32bn₩19.63bn
Debt—₩43.66bn₩43.94bn₩41.84bn₩574.4m₩1.50bn₩1.88bn—₩7.63bn₩2.33bn
Shareholders' equity₩154.72bn₩167.28bn₩74.08bn₩69.51bn₩55.95bn₩90.66bn₩132.01bn₩156.96bn−₩85.96bn−₩12.10bn
Shares outstanding55m48m48m48m47m46m45m45m19m19m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−₩41.25bn−₩69.40bn−₩28.36bn₩72.13bn−₩40.61bn−₩47.29bn−₩23.86bn−₩12.67bn−₩7.14bn−₩3.12bn
Capital spending−₩20.67bn−₩9.06bn−₩5.84bn−₩2.06bn−₩1.24bn−₩434.7m−₩1.59bn−₩1.15bn−₩802.5m−₩2.13bn
Free cash flow−₩61.92bn−₩78.46bn−₩34.21bn₩70.08bn−₩41.85bn−₩47.73bn−₩25.45bn−₩13.82bn−₩7.95bn−₩5.24bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩19.70bn₩13.14bn—₩1.44bn₩75.74bn₩2.16bn₩9.09bn₩7.94bn
Gross profit₩19.70bn₩13.14bn—₩1.44bn₩75.74bn₩2.16bn₩9.09bn₩7.94bn
Operating income−₩16.81bn−₩17.23bn−₩29.56bn−₩22.41bn₩40.73bn−₩29.03bn−₩19.93bn−₩13.89bn
Net income−₩14.72bn−₩14.48bn−₩28.16bn−₩21.27bn₩39.78bn−₩28.15bn−₩19.00bn−₩13.15bn
Diluted earnings per share-262.90-258.59-510.89-385.87819.65-580.04-393.56-273.64
Cash from operations−₩23.41bn₩32.84bn−₩23.63bn−₩27.56bn₩38.30bn−₩28.36bn−₩69.40bn−₩53.84bn
Capital spending−₩552.0m−₩243.0m−₩2.78bn−₩2.03bn−₩8.47bn−₩7.39bn−₩9.06bn−₩5.50bn
Free cash flow−₩23.97bn₩32.60bn−₩26.40bn−₩29.59bn₩29.83bn−₩35.76bn−₩78.46bn−₩59.34bn
Total assets₩273.72bn₩298.13bn₩280.93bn₩234.99bn₩244.19bn₩210.72bn₩231.98bn₩244.64bn
Cash and short-term investments—————₩107.71bn₩140.66bn₩154.24bn
Debt—————₩22.7m₩25.8m₩43.00bn
Shareholders' equity₩171.47bn₩180.63bn₩154.72bn₩182.27bn₩183.83bn₩143.03bn₩167.28bn₩180.79bn

Financial ratios

Data as of 26 Aug 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Gross margin100.0%100.0%100.0%100.0%100.0%100.0%——
Operating margin-50.8%-177.8%-4.0%1.3%-981.0%-736.0%——
Net margin-47.6%-166.2%-4.0%4.8%-816.9%-686.1%——
Return on equity-24.4%-33.2%-3.6%4.6%-77.8%-61.3%——
Return on assets-13.5%-23.9%-1.7%1.7%-66.5%-55.7%——
Free cash flow yield———————-0.3%
Revenue growth137.6%-49.0%-2.6%1162.2%-34.2%103.2%——
Earnings growth-31.9%1998.1%-182.5%-107.4%-21.7%50.3%——
Current ratio1.43x2.28x1.81x1.12x5.20x9.03x——
Debt to equity—0.00x0.58x0.58x0.00x0.00x0.00x—
Equity ratio55.1%72.1%46.3%37.5%85.5%90.8%——
Interest coverage-40.56x-1647.36x-1.22x0.68x-1246.02x-818.77x——
R&D as a share of sales117.2%221.8%79.4%71.9%769.6%651.5%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue5.6%57.8%—
Operating income—-7.6%—
Net income—-7.4%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin100.0%100.0%100.0%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings-291.6-26.0-445.1341.6-23.9-25.9-29.6-7.6
Price to sales138.943.218.016.3195.3177.5274.3—

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.